Published in Cell Cycle on October 02, 2015
The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr Biol (2007) 6.17
Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov (2010) 3.84
Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci U S A (2003) 2.81
Plk1 inhibition enhances the efficacy of androgen signaling blockade in castration-resistant prostate cancer. Cancer Res (2014) 2.23
Inhibition of NF-kappaB activation by pyrrolidine dithiocarbamate prevents In vivo expression of proinflammatory genes. Circulation (1999) 1.98
Arsenic alters cytosine methylation patterns of the promoter of the tumor suppressor gene p53 in human lung cells: a model for a mechanism of carcinogenesis. Mutat Res (1997) 1.74
Arsenic in drinking water and lung cancer: a systematic review. Environ Res (2008) 1.43
Role for Plk1 phosphorylation of Hbo1 in regulation of replication licensing. Proc Natl Acad Sci U S A (2008) 1.42
Methylarsenicals and arsinothiols are potent inhibitors of mouse liver thioredoxin reductase. Chem Res Toxicol (1999) 1.26
Plk1-mediated phosphorylation of Topors regulates p53 stability. J Biol Chem (2009) 1.26
Phosphorylation of CLIP-170 by Plk1 and CK2 promotes timely formation of kinetochore-microtubule attachments. EMBO J (2010) 1.24
Polo-like kinase 1 phosphorylation of G2 and S-phase-expressed 1 protein is essential for p53 inactivation during G2 checkpoint recovery. EMBO Rep (2010) 1.24
Plk1 phosphorylation of Orc2 promotes DNA replication under conditions of stress. Mol Cell Biol (2011) 1.21
Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells. Nat Commun (2011) 1.12
The molecular mechanisms of arsenic-induced cell transformation and apoptosis. Environ Health Perspect (2002) 1.10
Polo-like kinase 1 phosphorylation of p150Glued facilitates nuclear envelope breakdown during prophase. Proc Natl Acad Sci U S A (2010) 1.07
Plk1 protein phosphorylates phosphatase and tensin homolog (PTEN) and regulates its mitotic activity during the cell cycle. J Biol Chem (2014) 1.07
Arsenic toxicity is enzyme specific and its affects on ligation are not caused by the direct inhibition of DNA repair enzymes. Mutat Res (1998) 1.06
Arsenic trioxide-induced mitotic arrest and apoptosis in acute promyelocytic leukemia cells. Leukemia (2003) 1.05
Plk1-dependent microtubule dynamics promotes androgen receptor signaling in prostate cancer. Prostate (2013) 1.04
Plk1 phosphorylation of orc2 and hbo1 contributes to gemcitabine resistance in pancreatic cancer. Mol Cancer Ther (2012) 1.02
Induction of cytoplasmic accumulation of p53: a mechanism for low levels of arsenic exposure to predispose cells for malignant transformation. Cancer Res (2008) 1.02
Plk1 phosphorylation of PTEN causes a tumor-promoting metabolic state. Mol Cell Biol (2014) 0.99
The substrates of Plk1, beyond the functions in mitosis. Protein Cell (2010) 0.97
PLK1 Is transcriptionally activated by NF-κB during cell detachment and enhances anoikis resistance through inhibiting β-catenin degradation in esophageal squamous cell carcinoma. Clin Cancer Res (2011) 0.90
HSP70 colocalizes with PLK1 at the centrosome and disturbs spindle dynamics in cells arrested in mitosis by arsenic trioxide. Arch Toxicol (2014) 0.90
Arsenic exposure and bladder cancer: quantitative assessment of studies in human populations to detect risks at low doses. Toxicology (2014) 0.89
Low-dose arsenic induces chemotherapy protection via p53/NF-κB-mediated metabolic regulation. Oncogene (2013) 0.89
Association of inorganic arsenic exposure with liver cancer mortality: A meta-analysis. Environ Res (2014) 0.85
Proteomic identification of Hsp70 as a new Plk1 substrate in arsenic trioxide-induced mitotically arrested cells. Proteomics (2011) 0.85
Non-melanoma skin cancer: occupational risk from UV light and arsenic exposure. Rev Environ Health (2014) 0.85
A low-dose arsenic-induced p53 protein-mediated metabolic mechanism of radiotherapy protection. J Biol Chem (2014) 0.84
Sequential activation of Elk-1/Egr-1/GADD45α by arsenic. Oncotarget (2014) 0.83
Arsenic reverses glioblastoma resistance to mTOR-targeted therapies. Cell Cycle (2013) 0.82
Arsenic trioxide suppresses paclitaxel-induced mitotic arrest. Cell Prolif (2009) 0.82
Arsenate toxicity in human erythrocytes: characterization of morphologic changes and determination of the mechanism of damage. J Toxicol Environ Health A (1998) 0.81
Filamin A phosphorylation by Akt promotes cell migration in response to arsenic. Oncotarget (2015) 0.81